By Fineline Cube Shionogi & Co., Ltd. (TYO: 4507) announced that it has entered into a joint research agreement with Nagasaki University and the not-for-profit research and development organization, Medicines for Malaria Venture (MMV), for the discovery of a novel malaria prevention drug.
Partnership Framework & Funding
| Component | Detail |
|---|---|
| Parties | Shionogi & Co., Ltd.; Nagasaki University; Medicines for Malaria Venture (MMV) |
| Funding Source | Global Health Innovative Technology Fund (GHIT Fund) |
| Funding Amount | Approximately JPY 910 million (~USD 6.2 million) |
| Announcement Date | 13 Jul 2026 |
| Development Candidate | S-048133 (identified from ongoing collaboration) |
| Research Phase | Preclinical development |
This expanded collaboration builds upon a successful partnership initiated in March 2023, which has now yielded a promising development candidate for malaria prevention.
Research Background & Progress
- Initial Collaboration Start: March 2023
- Original Objective: Discovery of new antimalarial treatments and preventive drugs
- Current Milestone: Identification of development candidate S-048133
- Next Phase: Joint preclinical development under expanded agreement
- Funding Recognition: Selected for GHIT Fund support based on scientific merit and global health impact potential
Malaria remains one of the world’s most significant infectious disease challenges, with an estimated 249 million cases and 608,000 deaths globally in 2022, primarily affecting children under five in sub-Saharan Africa.
Strategic Partnership Dynamics
Shionogi & Co., Ltd. (TYO: 4507)
- Role: Pharmaceutical development expertise and compound optimization
- Core Competency: Anti-infective drug discovery and development
- Global Health Commitment: Long-standing involvement in infectious disease therapeutics
Nagasaki University
- Role: Academic research leadership and malaria expertise
- Core Competency: Tropical medicine and parasitology research
- Geographic Advantage: Historical focus on infectious diseases in Asia-Pacific region
Medicines for Malaria Venture (MMV)
- Role: Product development partnership coordination and global access strategy
- Core Competency: Antimalarial drug development and deployment
- Mission Alignment: Dedicated to reducing malaria burden in endemic countries
The tripartite collaboration leverages complementary strengths across industry, academia, and global health non-profit sectors.
Global Health Context & Market Need
| Metric | Current Status | Impact of S-048133 |
|---|---|---|
| Global Malaria Burden | 249 million cases annually | Potential prevention tool |
| At-Risk Population | 3.7 billion people globally | Expanded protection coverage |
| Current Prevention Options | Limited chemoprevention agents | Novel mechanism of action |
| Drug Resistance Concerns | Growing resistance to existing agents | New chemical class potential |
| Vulnerable Populations | Children, pregnant women, travelers | Targeted prevention strategies |
The development of new malaria prevention drugs is critical given increasing resistance to current antimalarial agents and the need for diverse intervention tools to support elimination efforts.
GHIT Fund Support Significance
- Funding Amount: JPY 910 million represents substantial non-dilutive funding
- Selection Criteria: Based on scientific innovation, feasibility, and global health impact
- Strategic Validation: GHIT Fund’s backing validates the project’s potential significance
- Implementation Timeline: Accelerated preclinical development enabled by dedicated funding
- Global Access Commitment: Aligns with GHIT Fund’s mission of equitable access to innovations
The GHIT Fund is a Japanese public-private partnership that supports R&D for neglected diseases affecting low- and middle-income countries.
Development Pipeline & Next Steps
- Current Stage: Preclinical development of S-048133
- Development Pathway: IND-enabling studies leading to clinical trials
- Regulatory Strategy: Coordination with international regulatory authorities
- Manufacturing Planning: Scalable production process development
- Access Planning: Early engagement with malaria-endemic country stakeholders
The timeline for clinical development will depend on successful completion of preclinical studies, with Phase I trials potentially commencing within 18-24 months.
Strategic Implications
- Global Health Leadership: Positions Shionogi as contributor to major infectious disease challenge
- Scientific Innovation: Advances novel chemical approaches to malaria prevention
- Partnership Model: Demonstrates effective industry-academia-nonprofit collaboration
- Sustainable Development Goals: Contributes to SDG 3 (Good Health and Well-being)
- Commercial-Social Balance: Addresses unmet medical need while building scientific reputation
Forward‑Looking Statements
This brief contains forward-looking statements regarding research progress, development timelines, and funding utilization. Actual results may differ due to risks including research outcomes, regulatory requirements, and global health policy changes.-Fineline Info & Tech